Abstract

NUT midline carcinoma (NMC) is a very rare, highly malignant disease with a specific cytogenetic abnormality t(15;19)(q14;p13.1). This tumor can occur throughout life, unfortunately, most cases are characterized by the presence of metastases at the time of diagnosis. There are clear cytogenetic and molecular-biological criterias for diagnosis. There are no specific standards of therapy that provide effective treatment of this pathology in the world. However, the presence of a chimeric oncogene characterizing the tumor is promising in terms of targeting drug research in the framework of international cooperation. It is also necessary to collect information about this rare disease to analyze it and to identify the most effective therapy method. This article presents an analysis of the clinical case of NMC, first diagnosed in a child of 9-yearsold in the Republic of Belarus.

Highlights

  • There are no specific standards of therapy that provide effective treatment of this pathology in the world

  • The presence of a chimeric oncogene characterizing the tumor is promising in terms of targeting drug research in the framework of international cooperation

  • This article presents an analysis of the clinical case of NUT midline carcinoma (NMC), first diagnosed in a child of 9-yearsold in the Republic of Belarus

Read more

Summary

Introduction

NUT midline carcinoma (NMC) is a very rare, highly malignant disease with a specific cytogenetic abnormality t(15;19)(q14;p13.1). Введение NUT midline carcinoma (NMC) – это очень редкое, агрессивное, генетически определенное заболевание [1]. Недавнее исследование [17], в котором было описано 38 опубликованных случаев первичного внутригрудного NMC, показало, что только 14 из них были локализованы в средостении, в то время как 19 наблюдений имели легочное происхождение, еще 2 случая были получены из тимуса и 3, как сообщалось, внутригрудные.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call